# Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

> **NCT02166476** · PHASE3 · COMPLETED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 550 (actual)

## Conditions studied

- Urinary Tract Infection Complicated
- Acute Pyelonephritis

## Interventions

- **DRUG:** Meropenem-Vaborbactam
- **DRUG:** Piperacillin-Tazobactam
- **DRUG:** Levofloxacin
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02166476
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-20
- **Primary completion:** 2016-04-28
- **Final completion:** 2016-04-28
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2018-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166476, "Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02166476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*